Johnson & Johnson Stock Price, News & Analysis

Johnson & Johnson (NYSE: JNJ) has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference scheduled for June 11th, 2025. The company's management will engage in a Fireside Chat session at 3:20 p.m. Eastern Time.

Investors and interested parties can access the live audio webcast through Johnson & Johnson's website at www.investor.jnj.com. A replay of the webcast will be made available approximately 48 hours after the event.

Johnson & Johnson has received FDA approval for IMAAVY™ (nipocalimab-aahu), a groundbreaking FcRn blocker for treating generalized myasthenia gravis (gMG). The treatment is approved for both adult and pediatric patients aged 12 and older who are anti-AChR or anti-MuSK antibody positive, covering over 90% of antibody-positive gMG patients.

Key highlights from clinical trials:

• Demonstrated 20 months of lasting disease control and symptom relief
• Reduced harmful IgG autoantibody levels by up to 75% from first dose
• Showed superior disease control over 24 weeks compared to placebo
• Maintained consistent safety profile in both adult and pediatric populations

Through the IMAAVY withMe program, commercially insured U.S. patients may receive their first treatment within one week and could pay as little as $0 per infusion. The approval follows FDA Priority Review designation and represents a significant advancement in gMG treatment options.

Johnson & Johnson (NYSE: JNJ) has announced its upcoming participation in Bernstein's 41st Annual Strategic Decisions Conference. The event will take place on Wednesday, May 28th, 2025, featuring a Fireside Chat session scheduled for 10:00 a.m. Eastern Time.

Key Details:

• The presentation will be accessible through a live audio webcast
• Investors can access the webcast via www.investor.jnj.com
• An archived version will be available later the same day
• Audio webcast replay will be accessible approximately 48 hours after the event

This conference participation demonstrates Johnson & Johnson's commitment to maintaining transparent communication with investors and analysts. The format of a Fireside Chat suggests an informal, conversational approach to discussing company strategies and developments.

Johnson & Johnson (NYSE: JNJ) announced promising first results from Cohort 4 of the Phase 2b SunRISe-1 study evaluating TAR-200, an intravesical gemcitabine releasing system for bladder cancer treatment. The study demonstrated:

• Over 80% disease-free survival (DFS) rate without reinduction
• 94% of patients preserved their bladder, avoiding radical cystectomy
• 85.3% and 81.1% DFS rates at six and nine months respectively
• 95.6% progression-free survival rate at 9 months

Among 52 enrolled patients, TAR-200's safety profile showed mostly low-grade, quickly resolving treatment-related adverse events. Common side effects included dysuria (40.4%), pollakiuria (30.8%), and urgency (26.9%). The results support continued evaluation in the ongoing Phase 3 SunRISe-5 study comparing TAR-200 to chemotherapy in BCG-pretreated patients.